GAR05 for COVID-19

GAR05 may be beneficial for COVID-19 according to the study below. COVID-19 involves the interplay of 500+ viral and host proteins and factors providing many therapeutic targets. Scientists have proposed 12,000+ potential treatments. c19early.org analyzes 220+ treatments. We have not reviewed GAR05 in detail.

Protocol efficacy and cost by country

Treatment protocols varied widely

November 2026
Efficacy of protocol
SeychellesSCIcelandISBelizeBZMaltaMTLuxembourgLUMontenegroMEBhutanBTGuyanaGYComorosKMFijiFJDjiboutiDJCyprusCYMauritiusMUEstoniaEETrinidad and TobagoTTEquatorial GuineaGQBahrainBHLatviaLVGuinea-BissauGWSloveniaSINorth MacedoniaMKLesothoLSGabonGABotswanaBWGambiaGMNamibiaNALithuaniaLTAlbaniaALQatarQAJamaicaJMArmeniaAMMongoliaMNBosnia and HerzegovinaBAUruguayUYEritreaERGeorgiaGECroatiaHRPanamaPAMauritaniaMRNew ZealandNZCentral African RepublicCFIrelandIELiberiaLRCosta RicaCRNorwayNOSlovakiaSKCongoCGFinlandFIDenmarkDKSingaporeSGEl SalvadorSVKyrgyzstanKGNicaraguaNILebanonLBLibyaLYBulgariaBGParaguayPYHong KongHKSierra LeoneSLTogoTGSwitzerlandCHIsraelILSerbiaRSPapua New GuineaPGAustriaATBelarusBYTajikistanTJHungaryHUUnited Arab EmiratesAEHondurasHNSwedenSEAzerbaijanAZPortugalPTJordanJOGreeceGRCzechiaCZDominican RepublicDOSouth SudanSSCubaCUHaitiHTBelgiumBEBoliviaBOTunisiaTNBurundiBIBeninBJRwandaRWGuineaGNZimbabweZWChadTDCambodiaKHSenegalSNNetherlandsNLSyriaSYEcuadorECGuatemalaGTZambiaZMKazakhstanKZMalawiMWRomaniaROMaliMLBurkina FasoBFSri LankaLKTaiwanTWNigerNEAustraliaAUCôte d'IvoireCICameroonCMMadagascarMGVenezuelaVENepalNPYemenYEGhanaGHMozambiqueMZMalaysiaMYAngolaAOPeruPEUzbekistanUZSaudi ArabiaSAMoroccoMACanadaCAPolandPLAfghanistanAFIraqIQUkraineUASudanSDAlgeriaDZArgentinaARUgandaUGSpainESColombiaCOSouth KoreaKRKenyaKEMyanmarMMSouth AfricaZAItalyITFranceFRUKGBThailandTHGermanyDEIranIRTurkeyTRDR CongoCDVietnamVNEgyptEGPhilippinesPHEthiopiaETJapanJPMexicoMXRussiaRUBangladeshBDNigeriaNGBrazilBRPakistanPKIndonesiaIDUSAUSIndiaINChinaCNmore effective, cheaperless effective, costlier
0%20%40%60%
$0$500$1,000$1,500
Cost per course

Cost and estimated efficacy of national COVID-19 protocols; area is proportional to population. Countries are named where there is room, with more populous countries first and in darker type; hover any dot for details.

Cui et al., Comprehensive Overview of Broadly Neutralizing Antibodies against SARS-CoV-2 Variants, Viruses, doi:10.3390/v16060900
Currently, SARS-CoV-2 has evolved into various variants, including the numerous highly mutated Omicron sub-lineages, significantly increasing immune evasion ability. The development raises concerns about the possibly diminished effectiveness of available vaccines and antibody-based therapeutics. Here, we describe those representative categories of broadly neutralizing antibodies (bnAbs) that retain prominent effectiveness against emerging variants including Omicron sub-lineages. The molecular characteristics, epitope conservation, and resistance mechanisms of these antibodies are further detailed, aiming to offer suggestion or direction for the development of therapeutic antibodies, and facilitate the design of vaccines with broad-spectrum potential.